Effect of LSD on Renal Function in Cirrhotic Patients With Portal Hypertension

NCT07811713 | Completed

• 1 other identifier: YZUC-025
• Study Type: observational
• Target: 496
• Locations: 0 countries
• Sites: N/A

Brief Summary

Patients with liver cirrhosis and portal hypertension often have impaired kidney function due to reduced blood flow to the kidneys and fluid buildup in the abdomen (ascites). Laparoscopy splenectomy and azygoportal disconnection (LSD) is a minimally invasive surgery commonly used to treat bleeding from swollen veins in these patients, but its impact on kidney function recovery remains unclear. This study will review medical records of patients with liver cirrhosis and portal hypertension who underwent LSD at our hospital. We will measure kidney function using estimated glomerular filtration rate (eGFR) before surgery and at 3, 6, 9, and 12 months after surgery to evaluate changes over time. We will also examine whether factors such as fluid buildup in the abdomen (ascites) before surgery are associated with kidney function changes after LSD. The goal is to better understand how LSD affects kidney function in these patients and to identify factors that may predict kidney function recovery, which could help improve care for cirrhotic patients undergoing this surgery.

Conditions

Cirrhosis, Liver; Splenectomy; Status; Renal Function Abnormal; Portal Hypertension

Keywords

Cirrhosis; Splenectomy; Laparoscopy; azygoportal disconnection; Renal function; Portal hypertension bleeding

Outcome Measures

Primary Outcomes (2)

• Serum Creatinine (Scr) Level

  Change in serum creatinine (Scr) level, used for eGFR calculation.

  At preoperative baseline, postoperative month 3, month 6, month 9, month 12

• Estimated Glomerular Filtration Rate (eGFR)

  Change in estimated glomerular filtration rate (eGFR) calculated using the 2021 CKD-EPI creatinine equation. eGFR was assessed at preoperative baseline and postoperative months 3, 6, 9, and 12 to evaluate longitudinal renal function changes.

  At preoperative baseline, postoperative month 3, month 6, month 9, month 12

Secondary Outcomes (5)

• Blood Urea Nitrogen (BUN) Level

  At preoperative baseline, postoperative month 3, month 6, month 9, month 12

• Blood Uric Acid (UA) Level

  At preoperative baseline, postoperative month 3, month 6, month 9, month 12

• Postoperative Complications

  At postoperative day 1, day 3, day 7, month 1, month 3, month 6, month 12

• Albumin

  At preoperative baseline, postoperative month 3, month 6, month 9, month 12

• Total Bilirubin Level

  At preoperative baseline, postoperative month 3, month 6, month 9, month 12

Study Arms (1)

LSD-treated Patients with Liver Cirrhosis and Portal Hypertension

Patients who underwent laparoscopy splenectomy and azygoportal disconnection for liver cirrhosis with portal hypertension

Procedure: Laparoscopic splenectomy and azygoportal disconnection

Interventions

Laparoscopic splenectomy and azygoportal disconnection PROCEDURE

A minimally invasive surgical procedure involving laparoscopic removal of the spleen and ligation of perigastric and esophageal varices to reduce portal hypertension and prevent variceal bleeding.

LSD-treated Patients with Liver Cirrhosis and Portal Hypertension

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a retrospective, single-center, observational cohort study. The study population consists of adult patients with liver cirrhosis, splenomegaly and hypersplenism, and portal hypertension bleeding who underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at the Department of Hepatobiliary Surgery, Subei People's Hospital Affiliated to Yangzhou University between February 2012 and February 2025. Patients were identified from electronic medical records and followed for up to 12 months postoperatively to assess renal function dynamics. The study aimed to evaluate the effect of LSD on renal function recovery and identify factors associated with postoperative renal outcomes in this high-risk population.

You may qualify if:

• Age ≥18 years.
• Diagnosis of liver cirrhosis with portal hypertension.
• Underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at our institution.
• Adequate preoperative and postoperative clinical and follow-up data for analysis.
• Preoperative and postoperative eGFR data available at the specified time points (baseline, month 3, 6, 9, and 12).

You may not qualify if:

• Child-Pugh Class C liver cirrhosis.
• Primary renal diseases (e.g., glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.).
• Previous abdominal surgery that precluded safe laparoscopic splenectomy and azygoportal disconnection (LSD).
• Severe cardiac, pulmonary, or cerebrovascular dysfunction; malignant tumors; or primary hematological disorders.
• Hepatic encephalopathy or refractory ascites within 1 month before surgery.
• Pregnancy or lactation.
• Poor compliance or inability to complete follow-up.

Sponsors & Collaborators

• Northern Jiangsu People's Hospital: lead

MeSH Terms

Conditions

Liver Cirrhosis; Hypertension, Portal; Fibrosis

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• guoqing jiang

  Clinical Medical College, Yangzhou University

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: August 11, 2026
• First Posted: September 10, 2026
• Study Start: February 1, 2012
• Primary Completion: February 1, 2026
• Study Completion: August 1, 2026
• Last Updated: September 10, 2026

Record last verified: 2026-09